Gennady Bratslavsky

Robotic-assisted Radical Nephrectomy With Retrohepatic Vena Caval Tumor Thrombectomy (Level III) Combined With Extended Retroperitoneal Lymph Node Dissection.

Chromophobe Renal Cell Carcinoma is the Most Common Nonclear Renal Cell Carcinoma in Young Women: Results from the SEER Database.

The dynamic interactome of human Aha1 upon Y223 phosphorylation.

Surgery: Routine adrenalectomy in renal cancer--an antiquated practice.

Argument in favor of performing partial nephrectomy for tumors greater than 7 cm: the metastatic prescription has already been written.

Feasibility and outcomes of laparoscopic renal intervention after prior open ipsilateral retroperitoneal surgery.

Economic burden of repeat renal surgery on solitary kidney--do the ends justify the means? A cost analysis.

Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitors.

Compared with radical nephrectomy, nephron-sparing surgery offers a long-term survival advantage in patients between the ages of 20 and 44 years with renal cell carcinomas (≤4 cm): an analysis of the SEER database.

Hereditary renal cell carcinoma: genetics, clinical features, and surgical considerations.

Defining the radiobiology of prostate cancer progression: An important question in translational prostate cancer research.

Preoperative cross-sectional imaging allows for avoidance of unnecessary adrenalectomy during RCC surgery.

Renal cell carcinoma in young patients: a review of recent literature.

In Obese Patients, the Distance Between Skin and Renal Collecting System Changes with the Position of the Patient from Supine to Prone.

Loss of Wave1 gene defines a subtype of lethal prostate cancer.

Targeting Hsp90 in urothelial carcinoma.

Molecular mechanisms of tissue inhibitor of metalloproteinase 2 in the tumor microenvironment.

c-Abl Mediated Tyrosine Phosphorylation of Aha1 Activates Its Co-chaperone Function in Cancer Cells.

Mps1 Mediated Phosphorylation of Hsp90 Confers Renal Cell Carcinoma Sensitivity and Selectivity to Hsp90 Inhibitors.

Sixth BHD Symposium and First International Upstate Kidney Cancer Symposium: latest scientific and clinical discoveries.

Renal Mass Biopsy: Always, Sometimes, or Never?

Implications of High Rates of Metastatic Prostate Cancer in BRCA2 Mutation Carriers.

An Unusual Etiology of Urinary Retention - Small Cell Prostate Carcinoma.

The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding.

Pheochromocytoma in Urologic Practice.

The metastatic potential of renal tumors: Influence of histologic subtypes on definition of small renal masses, risk stratification, and future active surveillance protocols.

Surgical Techniques in the Management of Small Renal Masses.

Comparison of survival for partial vs. radical nephrectomy in young patients with T1a renal cell carcinoma treated at commission on cancer-accredited facilities and influence of comorbidities on treatment choice.

Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients.

Phosphorylation and Ubiquitination Regulate Protein Phosphatase 5 Activity and Its Prosurvival Role in Kidney Cancer.

Pathological upstaging of clinical T1 renal cell carcinoma: an analysis of 115,835 patients from National Cancer Data Base, 2004-2013.

Sporadic renal angiomyolipoma in a patient with Birt-Hogg-Dubé: chaperones in pathogenesis.

Is pelvic lymph node dissection necessary in patients with biopsy proven Gleason 6 prostate cancer? - analysis of the SEER database.